

Acknowledgement and Consent for Disclosure of Potential Conflict(s) of Interest  
and Waiver under 18 U.S.C. §208(b)(3)

Morris Schambelan, M.D.

**Committees:** Endocrinologic & Metabolic Drugs and the Drug Safety and Risk  
Management Advisory Committees

**Meeting Dates:** July 30, 2007

I acknowledge that contingent upon public disclosure of the financial interests listed below, related to the discussions of the cardiovascular ischemic/thrombotic risks of the thiazolidinediones, with focus on rosiglitazone, as presented by the FDA and GlaxoSmithKline. I am eligible to receive a waiver under 18 U.S.C. §208(b)(3).

<b>Type of Interest</b>	<b>Nature</b>	<b>Magnitude</b>
Member of Complications Committee	Competing Firm	Less than \$10,001 per year

I hereby request that FDA make this information publicly available on my behalf. I understand that without public disclosure of these interests the waivers are not valid.

      /S/        
Signature of SGE

      6/25/2007        
Date